MEK Inhibitor News and Research

RSS

Tafinlar, Mekinist get FDA approval to treat patients with advanced melanoma

The U.S. Food and Drug Administration today approved two new drugs, Tafinlar (dabrafenib) and Mekinist (trametinib), for patients with advanced (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.

30 May 2013

Trovagene, MD Anderson partner to detect transrenal BRAF mutations in metastatic cancers

Trovagene, Inc., a developer of transrenal molecular diagnostics, announced that it has entered into a clinical collaboration with The University of Texas MD Anderson Cancer Center to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers.

3 Jan 2013

MITF protein may help develop effective drug treatments for melanoma

Scientists at The University of Manchester have identified a protein that appears to hold the key to creating more effective drug treatments for melanoma, one of the deadliest cancers.

From The University of Manchester 19 Dec 2012

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

AstraZeneca today announced the presentation of important new data from studies of FASLODEX (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas.

5 Dec 2012

Paper illuminates importance of PKM2 in cancer development and progression

Researchers at The University of Texas MD Anderson Cancer Center have tracked down a cancer-promoting protein's pathway into the cell nucleus and discovered how, once there, it fires up a glucose metabolism pathway on which brain tumors thrive.

26 Nov 2012

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2013.

30 Oct 2012

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma.

1 Oct 2012

Sorafenib does not improve overall survival among patients with NSCLC

Treatment with the drug sorafenib as a third or fourth line therapy does not result in improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to findings released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. However, a post-hoc biomarker analysis of the trial data that was also presented suggests that patients with EGFR-mutant tumors may benefit.

29 Sep 2012

Drug combinations show promise against metastatic melanoma

Promising new data on drug combinations to treat metastatic melanoma are presented at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

29 Sep 2012

Exelixis announces preliminary results from BRIM7 Phase Ib trial on BRAFV600 mutated MM

Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.

29 Sep 2012

Novel drug combination for patients with NRAS-mutant melanoma

A new study published online in Nature Medicine, led by scientists at The University of Texas MD Anderson Cancer Center, describes the discovery of a novel drug combination aimed at a subset of melanoma patients who currently have no effective therapeutic options.

17 Sep 2012

PD0325901 drug may hold potential to prevent neurofibromatosis 1 in children

A drug originally developed to stop cancerous tumors may hold the potential to prevent abnormal brain cell growth and learning disabilities in some children, if they can be diagnosed early enough, a new animal study suggests.

31 Aug 2012

BRAF L597 mutation in melanoma patients responds to MEK inhibitor drugs

An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to MEK inhibitor drugs, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation.

17 Jul 2012

Promising results for dabrafenib in advanced melanoma

The BRAF inhibitor dabrafenib shows promising results for treatment of advanced melanoma, both alone and in combination with the MEK inhibitor trametinib, show results from two studies presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA.

8 Jun 2012

Promising data from Array BioPharma’s MEK162 Phase 2 trial on BRAF and NRAS mutant melanoma

Promising data on MEK162 in an ongoing Phase 2 trial of patients with BRAF and NRAS mutated advanced melanoma was presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

5 Jun 2012

Array BioPharma third quarter revenue increases to $19.1M

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2012.

2 May 2012

Nature journal publishes first volume of Cancer Cell Line Encyclopedia

The goal of cancer treatment is to match the right drug to the right target in the right patient. But before such "personalized" drugs can be developed, more knowledge is needed about specific genomic alterations in cancers and their sensitivity to potential therapeutic agents.

29 Mar 2012

Melanoma drug makes pre-existing cells with RAS mutation grow into skin squamous cell cancers

Patients with metastatic melanoma taking the recently approved drug vemurafenib (Zelboraf) responded well to the twice daily pill, but some of them developed a different, secondary skin cancer.

18 Jan 2012

Combination of MEK inhibitors and nilotinib can overcome CML resistance to targeted drug

Cancer Research UK-funded scientists at The Institute of Cancer Research (ICR) have revealed a technique to kill chronic myeloid leukaemia (CML) cells that have stopped responding to a targeted drug, according to research published in Cancer Cell today.

9 Dec 2011

Receptor tyrosine kinases control PI3K signaling in human KRAS mutant colorectal cancers

Some cancers can be effectively treated with drugs inhibiting proteins known as receptor tyrosine kinases, but not those cancers caused by mutations in the KRAS gene. A team of researchers led by Jeffrey Engelman, at Massachusetts General Hospital Cancer Center, Boston, has now identified a potential way to effectively use receptor tyrosine kinases inhibitors to treat individuals with KRAS mutant colorectal cancers - combine them with inhibitors of the MEK/ERK signaling pathway.

11 Oct 2011

MEK Inhibitor News and Research

Tafinlar, Mekinist get FDA approval to treat patients with advanced melanoma

Trovagene, MD Anderson partner to detect transrenal BRAF mutations in metastatic cancers

MITF protein may help develop effective drug treatments for melanoma

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

Paper illuminates importance of PKM2 in cancer development and progression

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Sorafenib does not improve overall survival among patients with NSCLC

Drug combinations show promise against metastatic melanoma

Exelixis announces preliminary results from BRIM7 Phase Ib trial on BRAFV600 mutated MM

Novel drug combination for patients with NRAS-mutant melanoma

PD0325901 drug may hold potential to prevent neurofibromatosis 1 in children

BRAF L597 mutation in melanoma patients responds to MEK inhibitor drugs

Promising results for dabrafenib in advanced melanoma

Promising data from Array BioPharma’s MEK162 Phase 2 trial on BRAF and NRAS mutant melanoma

Array BioPharma third quarter revenue increases to $19.1M

Nature journal publishes first volume of Cancer Cell Line Encyclopedia

Melanoma drug makes pre-existing cells with RAS mutation grow into skin squamous cell cancers

Combination of MEK inhibitors and nilotinib can overcome CML resistance to targeted drug

Receptor tyrosine kinases control PI3K signaling in human KRAS mutant colorectal cancers

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News